Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,952 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study.
Zhu Y, Wang E, Zhao S, Han D, Zhao Y, Chen H, Zhu J, Han T, Bai Y, Lou Y, Zhang Y, Yang M, Zuo L, Fan J, Chen X, Jia J, Wu W, Ren W, Bai T, Ma S, Xu F, Tang Y, Han Y, Zhao J, Qi X, Li J, Du X, Chen D, Liu L. Zhu Y, et al. Among authors: wang e. Front Oncol. 2023 Jan 27;12:983554. doi: 10.3389/fonc.2022.983554. eCollection 2022. Front Oncol. 2023. PMID: 36776366 Free PMC article.
Potential candidates for liver resection in liver-confined advanced HCC: a Chinese multicenter observational study.
Bai T, Wang E, Zhao S, Han D, Zhao Y, Chen H, Zhu J, Han T, Bai Y, Lou Y, Zhang Y, Yang M, Zuo L, Fan J, Chen X, Jia J, Wu W, Ren W, Zhu Y, Ma S, Xu F, Tang Y, Du X, Zhao J, Li J, Qi X, Han Y, Chen D, Liu L. Bai T, et al. Among authors: wang e. Front Oncol. 2023 Jun 26;13:1170923. doi: 10.3389/fonc.2023.1170923. eCollection 2023. Front Oncol. 2023. PMID: 37434986 Free PMC article.
Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization.
Xia D, Wang Q, Bai W, Wang E, Wang Z, Mu W, Sun J, Huang M, Yin G, Li H, Zhao H, Zhang C, Li J, Wu J, Zhu X, Yang S, Pan X, Li J, Li Z, Xu G, Shi H, Zhang H, Zhang Y, Ding R, Yu H, Zheng L, Yang X, Wang G, You N, Feng L, Zhang S, Huang W, Xu T, Fan W, Li X, Yang X, Zhou W, Wang W, Li X, Wang Z, Luo B, Niu J, Yuan J, Lv Y, Li K, Guo W, Yin Z, Fan D, Xia J, Han G; China HCC-TACE Study Group. Xia D, et al. Among authors: wang g, wang w, wang e, wang z, wang q. Eur Radiol. 2022 Sep;32(9):5799-5810. doi: 10.1007/s00330-022-08716-4. Epub 2022 Apr 6. Eur Radiol. 2022. PMID: 35381853
Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
Xia D, Bai W, Wang E, Li J, Chen X, Wang Z, Huang M, Huang M, Sun J, Yang W, Lin Z, Wu J, Li Z, Yang S, Zhu X, Chen Z, Zhang Y, Fan W, Mai Q, Ding R, Nie C, Feng L, Li X, Huang W, Sun J, Wang Q, Lv Y, Li X, Luo B, Wang Z, Yuan J, Guo W, Li K, Li B, Li R, Yin Z, Xia J, Han G. Xia D, et al. Among authors: wang e, wang z, wang q. Liver Cancer. 2022 Mar 9;11(4):368-382. doi: 10.1159/000523849. eCollection 2022 Jul. Liver Cancer. 2022. PMID: 35978600 Free PMC article.
Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX, Wang EX, Bai W, Xia DD, Mu W, Li J, Yang QY, Huang M, Xu GH, Sun JH, Li HL, Zhao H, Wu JB, Yang SF, Li JP, Li ZX, Zhang CQ, Zhu XL, Zheng YB, Wang QH, Li J, Yuan J, Li XM, Niu J, Yin ZX, Xia JL, Fan DM, Han GH, On Behalf Of China Hcc-Tace Study Group. Wang ZX, et al. World J Gastroenterol. 2020 Feb 14;26(6):657-669. doi: 10.3748/wjg.v26.i6.657. World J Gastroenterol. 2020. PMID: 32103874 Free PMC article.
7,952 results